The FDA's green light for the submission of Amicus Therapeutics Inc.'s new drug application (NDA) for migalastat in Fabry disease followed what John Crowley, chairman and CEO, called a "data-driven, science-based discussion" with "largely the same reviewers" within the same FDA review division who previously looked askance at the company's data package.